Targeting cancer-specific mutagenic genes such as KRAS and p53 has inhibited lung tumor growth, limited KRAS gene expression, regulated p53 expression, and enhanced chemo-sensitization to paclitaxel [66,67]. The gene discussed is TP53; the disease is cancer.